Gelteq Limited (GELS) AI Stock Analysis

Incorporated in 2017 and headquartered in Clayton, Australia, Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals. Its products serve markets across the United States of America, China, and Australia with a team of 7 employees. Gelteq provides edible delivery gels for prescription drugs, nutraceuticals, pet care, over-the-counter products, and sports use. The company completed its initial public offering in 2024 and trades on the NASDAQ exchange.

Gelteq generated revenue of $147,536 in FY2022, which fell 45.9% to $79,843 in FY2023 before rebounding 107.5% to $165,645 in FY2025, representing a two-year revenue CAGR of 6.0%. Net income remained deeply negative, moving from -$3.4M in FY2022 to -$3.5M in FY2023 and -$6.6M in FY2025, accompanied by a net margin of -4011.9%. Gross margin reached 100.0% in FY2025 compared to 35.7% in FY2022. For the trailing twelve months ended March 31, 2026, revenue stood at $471,799 with an operating margin of -1985.3% and quarterly revenue growth of 48.9% year-over-year.

As of March 31, 2026, Gelteq held $9,349 in cash and short-term investments against total debt of $5.1M, resulting in net debt of $5.1M and a current ratio of 0.09. Shareholders' equity was $14.2M out of $20.1M in total assets, yielding a debt-to-equity ratio of 0.36. In FY2025, operating cash flow was -$5.5M, free cash flow was -$6.2M, and capital expenditures totaled $642,234. The company does not conduct share repurchases or pay dividends, while 5-year share count increased 11.1%.

Gelteq trades at a price-to-sales multiple of 10.1x and an enterprise-value-to-revenue ratio of 84.1x, which compares to a median price-to-sales of 4.1x for US-listed Healthcare peers. Its price-to-book ratio is 0.6x. Over the past year, the stock fell 65.2% and is down 44.2% year-to-date, closing at $0.45 on October 16, 2026, which sits 34.4% below its 200-day average. Over the same 1-year period, the S&P 500 benchmark gained 16.8%.

Gelteq does not have tracked Wall Street analyst rating counts, earnings per share estimates, consensus price targets, or an announced next earnings date. The company reported trailing twelve months diluted earnings per share of -$0.44 through March 31, 2026, on trailing twelve months revenue of $471,799. Shares last closed at $0.45 on October 16, 2026, trading between a 52-week low of $0.39 and a 52-week high of $2.01 with a market cap of $4.8M.

This page is an AI-written research summary of Gelteq Limited (GELS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GELS income statement, GELS balance sheet, GELS key metrics, GELS chart. See the GELS stock overview for the latest quote and news.